Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis

NCT00674362 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00674362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00674362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2008
Completion date
December 31, 2010
Enrollment
194 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis